BioSpace News Archive

Ken Pienta, acting chief medical officer of Cue Biopharma, said the researchers believe that CUE-101 may lead to enhanced anti-tumor activity in combination with Merck’s powerhouse checkpoint inhibitor.

The interest in psychedelic medicine – particularly psilocybin, a pro-drug derived from some 200 varieties of the so-called magic mushrooms – stems from multiple factors.

The goal is to support the discovery and development of next-generation drug and engineered cell therapies, specifically with a focus on natural killer (NK) cells.

Biopharma and life sciences groups from across the globe provide updates on their business and pipelines.

Putting together research for publication can be a challenging and time-consuming process, heightened even further because of the current COVID-19 situation, during which non-essential labs have been hibernated and many researchers are now working separately and remotely, instead of collaborating within the same space.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 22, 2020.

This morning, the Switzerland-based company said its SPIRIT-2 study met its co-primary efficacy endpoints and six key secondary endpoints for endometriosis treatment.

Researchers at Switzerland-based Empa, ETH Zurich and Zurich University Hospital have developed a sensor that has the potential to identify SARS-CoV-2, the novel coronavirus that causes COVID-19, in the air.

A new life sciences facility dubbed The Labs has opened in Chicago providing necessary wet lab space for companies looking to expand their physical presence in the Windy City and cement the city’s reputation as a hub for cutting edge biomedical innovation.

After leading a flurry of collaborations with multiple companies to hasten the development of vaccine candidates and treatments for COVID-19, Rick Bright, the director of BARDA, has abruptly departed his post for another position in the government.